Keywords: seroquel, overtake, lamictal, biopolar, depression, says, report
"Seroquel will overtake Lamictal for biopolar depression," says report
Article | 26 February 2007
AstraZeneca's Seroquel (quetiapine) will overtake GlaxoSmithKline's Lamictal (lamotrigine) as the gold standard in the treatment of bipolar depression by 2010, according ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
